{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:12:02Z","timestamp":1793661122125,"version":"4.5.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007210","name":"RWTH Aachen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007210","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Traumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Several clinical investigations have compared different pharmacologic agents for the prophylaxis of venous thromboembolism (VTE). However, no consensus has been reached. The present investigation compared enoxaparin, fondaparinux, aspirin and non-vitamin K antagonist oral anticoagulants (NOACs) commonly used as prophylaxis following total hip arthroplasty (THA). A Bayesian network meta-analysis was performed, setting as outcomes of interest the rate of deep venous thrombosis (DVT), pulmonary embolism (PE) and major and minor haemorrhages.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension statement for reporting systematic reviews incorporating network meta-analyses of healthcare interventions. All randomised controlled trials (RCTs) comparing two or more drugs used for the prophylaxis of VTE following THA were accessed. PubMed, Web of Science and Google Scholar databases were accessed in March 2023 with no time constraint.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 31,705 patients were extracted. Of these, 62% (19,824) were women, with age, sex ratio, and body mass index (BMI) being comparable at baseline. Apixaban 5\u00a0mg, fondaparinux, and rivaroxaban 60\u00a0mg were the most effective in reducing the rate of DVT. Dabigatran 220\u00a0mg, apixaban 5\u00a0mg, and aspirin 100\u00a0mg were the most effective in reducing the rate of PE. Apixaban 5\u00a0mg, ximelagatran 2\u00a0mg and aspirin 100\u00a0mg were associated with the lowest rate of major haemorrhages, while rivaroxaban 2.5\u00a0mg, apixaban 5\u00a0mg and enoxaparin 40\u00a0mg were associated with the lowest rate of minor haemorrhages.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Administration of apixaban 5\u00a0mg demonstrated the best balance between VTE prevention and haemorrhage control following THA.<\/jats:p><jats:p><jats:italic>Level of evidence<\/jats:italic>Level I, network meta-analysis of RCTs.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s10195-023-00742-2","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T16:02:48Z","timestamp":1704816168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Antithrombotic prophylaxis following total hip arthroplasty: a level I Bayesian network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-1221","authenticated-orcid":false,"given":"Filippo","family":"Migliorini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Maffulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlis","family":"Velaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"K\u00e4mmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hildebrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf Krister","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Eschweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,9]]},"reference":[{"issue":"23","key":"742_CR1","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/jama.2019.19413","volume":"322","author":"D Metcalfe","year":"2019","unstructured":"Metcalfe D, Perry DC, Claireaux HA, Simel DL, Zogg CK, Costa ML (2019) Does this patient have hip osteoarthritis?: The rational clinical examination systematic review. JAMA 322(23):2323\u20132333. https:\/\/doi.org\/10.1001\/jama.2019.19413","journal-title":"JAMA"},{"issue":"11","key":"742_CR2","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s12325-016-0409-3","volume":"33","author":"NJ Murphy","year":"2016","unstructured":"Murphy NJ, Eyles JP, Hunter DJ (2016) Hip osteoarthritis: etiopathogenesis and implications for management. Adv Ther 33(11):1921\u20131946. https:\/\/doi.org\/10.1007\/s12325-016-0409-3","journal-title":"Adv Ther"},{"issue":"1","key":"742_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10195-023-00719-1","volume":"24","author":"J Descamps","year":"2023","unstructured":"Descamps J, Teissier V, Graff W, Mouton A, Bouche PA, Marmor S (2023) Managing early complications in total hip arthroplasty: the safety of immediate revision. J Orthop Traumatol 24(1):38. https:\/\/doi.org\/10.1186\/s10195-023-00719-1","journal-title":"J Orthop Traumatol"},{"issue":"7","key":"742_CR4","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s00264-018-4124-3","volume":"43","author":"F Migliorini","year":"2019","unstructured":"Migliorini F, Biagini M, Rath B, Meisen N, Tingart M, Eschweiler J (2019) Total hip arthroplasty: minimally invasive surgery or not? Meta-analysis of clinical trials. Int Orthop 43(7):1573\u20131582. https:\/\/doi.org\/10.1007\/s00264-018-4124-3","journal-title":"Int Orthop"},{"issue":"10158","key":"742_CR5","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/s0140-6736(18)31777-x","volume":"392","author":"RJ Ferguson","year":"2018","unstructured":"Ferguson RJ, Palmer AJ, Taylor A, Porter ML, Malchau H, Glyn-Jones S (2018) Hip replacement. Lancet 392(10158):1662\u20131671. https:\/\/doi.org\/10.1016\/s0140-6736(18)31777-x","journal-title":"Lancet"},{"issue":"9855","key":"742_CR6","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/s0140-6736(12)60607-2","volume":"380","author":"R Pivec","year":"2012","unstructured":"Pivec R, Johnson AJ, Mears SC, Mont MA (2012) Hip arthroplasty. Lancet 380(9855):1768\u20131777. https:\/\/doi.org\/10.1016\/s0140-6736(12)60607-2","journal-title":"Lancet"},{"issue":"5","key":"742_CR7","doi-asserted-by":"publisher","first-page":"6853","DOI":"10.3390\/app11156853","volume":"11","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Cipollaro L, Cuozzo F, Oliva F, Marino AV, Maffulli N (2021) Outpatient total hip arthroplasty: a meta-analysis. App Sci 11(5):6853. https:\/\/doi.org\/10.3390\/app11156853","journal-title":"App Sci"},{"key":"742_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/jcm10040621","volume":"10","author":"F Leiss","year":"2021","unstructured":"Leiss F, G\u00f6tz JS, Maderbacher G, Meyer M, Reinhard J, Zeman F, Grifka J, Greimel F (2021) Excellent functional outcome and quality of life after primary cementless total hip arthroplasty (THA) using an enhanced recovery setup. J Clin Med 10:4. https:\/\/doi.org\/10.3390\/jcm10040621","journal-title":"J Clin Med"},{"issue":"5","key":"742_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.5604\/01.3001.0010.5823","volume":"19","author":"A \u015awito\u0144","year":"2017","unstructured":"\u015awito\u0144 A, Wodka-Natkaniec E, Nied\u017awiedzki \u0141, Ga\u017adzik T, Nied\u017awiedzki T (2017) Activity and quality of life after total hip arthroplasty. Ortop Traumatol Rehabil 19(5):441\u2013450. https:\/\/doi.org\/10.5604\/01.3001.0010.5823","journal-title":"Ortop Traumatol Rehabil"},{"key":"742_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00003086-200109000-00019","volume":"390","author":"P S\u00f6derman","year":"2001","unstructured":"S\u00f6derman P, Malchau H, Herberts P (2001) Outcome of total hip replacement: a comparison of different measurement methods. Clin Orthop Relat Res 390:163\u2013172. https:\/\/doi.org\/10.1097\/00003086-200109000-00019","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"742_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2519\/jospt.2002.32.6.260","volume":"32","author":"E Trudelle-Jackson","year":"2002","unstructured":"Trudelle-Jackson E, Emerson R, Smith S (2002) Outcomes of total hip arthroplasty: a study of patients one year postsurgery. J Orthop Sports Phys Ther 32(6):260\u2013267. https:\/\/doi.org\/10.2519\/jospt.2002.32.6.260","journal-title":"J Orthop Sports Phys Ther"},{"issue":"1","key":"742_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10195-023-00711-9","volume":"24","author":"D Szymski","year":"2023","unstructured":"Szymski D, Walter N, Krull P, Melsheimer O, Schindler M, Grimberg A, Alt V, Steinbrueck A, Rupp M (2023) Comparison of mortality rate and septic and aseptic revisions in total hip arthroplasties for osteoarthritis and femoral neck fracture: an analysis of the German Arthroplasty Registry. J Orthop Traumatol 24(1):29. https:\/\/doi.org\/10.1186\/s10195-023-00711-9","journal-title":"J Orthop Traumatol"},{"key":"742_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jor.2023.07.016","volume":"43","author":"JA Dubin","year":"2023","unstructured":"Dubin JA, Bains SS, Chen Z, Hameed D, Moore MC, Mont MA, Nace J, Delanois RE (2023) Single center evaluation of outcomes of modular dual mobility liners during revision total hip arthroplasty: a five-year follow-up. J Orthop 43:75\u201378. https:\/\/doi.org\/10.1016\/j.jor.2023.07.016","journal-title":"J Orthop"},{"issue":"1","key":"742_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s10195-022-00636-9","volume":"23","author":"F Migliorini","year":"2022","unstructured":"Migliorini F, Cuozzo F, Oliva F, Eschweiler J, Hildebrand F, Maffulli N (2022) Imageless navigation for primary total hip arthroplasty: a meta-analysis study. J Orthop Traumatol 23(1):21. https:\/\/doi.org\/10.1186\/s10195-022-00636-9","journal-title":"J Orthop Traumatol"},{"issue":"11","key":"742_CR15","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.arth.2016.04.004","volume":"31","author":"VV An","year":"2016","unstructured":"An VV, Phan K, Levy YD, Bruce WJ (2016) Aspirin as thromboprophylaxis in hip and knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty 31(11):2608\u20132616. https:\/\/doi.org\/10.1016\/j.arth.2016.04.004","journal-title":"J Arthroplasty"},{"issue":"8","key":"742_CR16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1712746","volume":"378","author":"DR Anderson","year":"2018","unstructured":"Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, Pelet S, Fisher W, Belzile E, Dolan S, Crowther M, Bohm E, MacDonald SJ, Gofton W, Kim P, Zukor D, Pleasance S, Andreou P, Doucette S, Theriault C, Abianui A, Carrier M, Kovacs MJ, Rodger MA, Coyle D, Wells PS, Vendittoli PA (2018) Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med 378(8):699\u2013707. https:\/\/doi.org\/10.1056\/NEJMoa1712746","journal-title":"N Engl J Med"},{"issue":"5","key":"742_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/00063198-200209000-00004","volume":"8","author":"RH White","year":"2002","unstructured":"White RH, Henderson MC (2002) Risk factors for venous thromboembolism after total hip and knee replacement surgery. Curr Opin Pulm Med 8(5):365\u2013371. https:\/\/doi.org\/10.1097\/00063198-200209000-00004","journal-title":"Curr Opin Pulm Med"},{"key":"742_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jor.2023.04.013","volume":"40","author":"L Hoggett","year":"2023","unstructured":"Hoggett L, Alexander D, Helm A, Collaborative N (2023) Post-operative complications following total hip arthroplasty for trauma: a multicentre cohort study comparing dual mobility with conventional acetabular bearings. J Orthop 40:34\u201337. https:\/\/doi.org\/10.1016\/j.jor.2023.04.013","journal-title":"J Orthop"},{"issue":"11","key":"742_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00228-010-0889-z","volume":"66","author":"YB Cao","year":"2010","unstructured":"Cao YB, Zhang JD, Shen H, Jiang YY (2010) Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 66(11):1099\u20131108. https:\/\/doi.org\/10.1007\/s00228-010-0889-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"48","key":"742_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000013465","volume":"97","author":"HF Huang","year":"2018","unstructured":"Huang HF, Li SS, Yang XT, Xie Q, Tian XB (2018) Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: a meta-analysis. Medicine (Baltimore) 97(48):e13465. https:\/\/doi.org\/10.1097\/md.0000000000013465","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"742_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12891-020-3100-4","volume":"21","author":"V Mula","year":"2020","unstructured":"Mula V, Parikh S, Suresh S, Bottle A, Loeffler M, Alam M (2020) Venous thromboembolism rates after hip and knee arthroplasty and hip fractures. BMC Musculoskelet Disord 21(1):95. https:\/\/doi.org\/10.1186\/s12891-020-3100-4","journal-title":"BMC Musculoskelet Disord"},{"issue":"12","key":"742_CR22","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1177\/000313481508101220","volume":"81","author":"TE Newhook","year":"2015","unstructured":"Newhook TE, LaPar DJ, Walters DM, Gupta S, Jolissaint JS, Adams RB, Brayman KL, Zaydfudim VM, Bauer TW (2015) Impact of postoperative venous thromboembolism on postoperative morbidity, mortality, and resource utilization after hepatectomy. Am Surg 81(12):1216\u20131223","journal-title":"Am Surg"},{"issue":"1","key":"742_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3349\/ymj.2015.56.1.139","volume":"56","author":"SY Lee","year":"2015","unstructured":"Lee SY, du Ro H, Chung CY, Lee KM, Kwon SS, Sung KH, Park MS (2015) Incidence of deep vein thrombosis after major lower limb orthopedic surgery: analysis of a nationwide claim registry. Yonsei Med J 56(1):139\u2013145. https:\/\/doi.org\/10.3349\/ymj.2015.56.1.139","journal-title":"Yonsei Med J"},{"issue":"1","key":"742_CR24","first-page":"452","volume":"86","author":"JA Heit","year":"2001","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O\u2019Fallon WM, Melton LJ 3rd (2001) The epidemiology of venous thromboembolism in the community. Thromb Haemost 86(1):452\u2013463","journal-title":"Thromb Haemost"},{"issue":"3","key":"742_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/corr.0000000000000615","volume":"477","author":"M Sloan","year":"2019","unstructured":"Sloan M, Sheth N, Lee GC (2019) Is obesity associated with increased risk of deep vein thrombosis or pulmonary embolism after hip and knee arthroplasty? A large database study. Clin Orthop Relat Res 477(3):523\u2013532. https:\/\/doi.org\/10.1097\/corr.0000000000000615","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"742_CR26","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/s0025-6196(11)61526-7","volume":"80","author":"AK Jaffer","year":"2005","unstructured":"Jaffer AK, Barsoum WK, Krebs V, Hurbanek JG, Morra N, Brotman DJ (2005) Duration of anesthesia and venous thromboembolism after hip and knee arthroplasty. Mayo Clin Proc 80(6):732\u2013738. https:\/\/doi.org\/10.1016\/s0025-6196(11)61526-7","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"742_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00402-015-2208-8","volume":"135","author":"J Zhang","year":"2015","unstructured":"Zhang J, Chen Z, Zheng J, Breusch SJ, Tian J (2015) Risk factors for venous thromboembolism after total hip and total knee arthroplasty: a meta-analysis. Arch Orthop Trauma Surg 135(6):759\u2013772. https:\/\/doi.org\/10.1007\/s00402-015-2208-8","journal-title":"Arch Orthop Trauma Surg"},{"issue":"3","key":"742_CR28","first-page":"95","volume":"9","author":"BS Gathof","year":"2004","unstructured":"Gathof BS, Picker SM, Rojo J (2004) Epidemiology, etiology and diagnosis of venous thrombosis. Eur J Med Res 9(3):95\u2013103","journal-title":"Eur J Med Res"},{"issue":"1","key":"742_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1055\/s-2001-14668","volume":"1","author":"C Kearon","year":"2001","unstructured":"Kearon C (2001) Epidemiology of venous thromboembolism. Semin Vasc Med 1(1):7\u201326. https:\/\/doi.org\/10.1055\/s-2001-14668","journal-title":"Semin Vasc Med"},{"issue":"11","key":"742_CR30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.5694\/mja2.50201","volume":"210","author":"PC Kruger","year":"2019","unstructured":"Kruger PC, Eikelboom JW, Douketis JD, Hankey GJ (2019) Deep vein thrombosis: update on diagnosis and management. Med J Aust 210(11):516\u2013524. https:\/\/doi.org\/10.5694\/mja2.50201","journal-title":"Med J Aust"},{"issue":"22","key":"742_CR31","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1182\/bloodadvances.2018024828","volume":"2","author":"W Lim","year":"2018","unstructured":"Lim W, Le Gal G, Bates SM, Righini M, Haramati LB, Lang E, Kline JA, Chasteen S, Snyder M, Patel P, Bhatt M, Patel P, Braun C, Begum H, Wiercioch W, Sch\u00fcnemann HJ, Mustafa RA (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv 2(22):3226\u20133256. https:\/\/doi.org\/10.1182\/bloodadvances.2018024828","journal-title":"Blood Adv"},{"issue":"1 Suppl","key":"742_CR32","doi-asserted-by":"publisher","first-page":"132s","DOI":"10.1378\/chest.119.1_suppl.132s","volume":"119","author":"WH Geerts","year":"2001","unstructured":"Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB (2001) Prevention of venous thromboembolism. Chest 119(1 Suppl):132s\u2013175s. https:\/\/doi.org\/10.1378\/chest.119.1_suppl.132s","journal-title":"Chest"},{"issue":"19","key":"742_CR33","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1001\/archinte.1993.00410190057007","volume":"153","author":"DN Mohr","year":"1993","unstructured":"Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM (1993) Prophylactic agents for venous thrombosis in elective hip surgery. Meta-analysis of studies using venographic assessment. Arch Intern Med 153(19):2221\u20132228","journal-title":"Arch Intern Med"},{"issue":"26","key":"742_CR34","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"BI Eriksson","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358(26):2765\u20132775. https:\/\/doi.org\/10.1056\/NEJMoa0800374","journal-title":"N Engl J Med"},{"key":"742_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.surge.2021.07.004","author":"F Migliorini","year":"2021","unstructured":"Migliorini F, Driessen A, Eschweiler J, Tingart M, Maffulli N (2021) No benefits of minimally invasive total hip arthroplasty via Watson-Jones approach: a retrospective cohort study. Surgeon. https:\/\/doi.org\/10.1016\/j.surge.2021.07.004","journal-title":"Surgeon"},{"issue":"8","key":"742_CR36","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.otsr.2020.02.026","volume":"106","author":"JY Jenny","year":"2020","unstructured":"Jenny JY, Bulaid Y, Boisrenoult P, Bonin N, Henky P, Tracol P, Chouteau J, Courtin C, Henry MP, Schwartz C, Mertl P, De Ladoucette A (2020) Bleeding and thromboembolism risk of standard antithrombotic prophylaxis after hip or knee replacement within an enhanced recovery program. Orthop Traumatol Surg Res 106(8):1533\u20131538. https:\/\/doi.org\/10.1016\/j.otsr.2020.02.026","journal-title":"Orthop Traumatol Surg Res"},{"issue":"18","key":"742_CR37","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1056\/NEJMoa011100","volume":"345","author":"Eriksson BI, Bauer KA, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Hip-Fracture Surgery S","year":"2001","unstructured":"Eriksson BI, Bauer KA, Lassen MR, Turpie AG, Steering Committee of the Pentasaccharide in Hip-Fracture Surgery S (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345(18):1298\u20131304. https:\/\/doi.org\/10.1056\/NEJMoa011100","journal-title":"N Engl J Med"},{"issue":"12","key":"742_CR38","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1111\/j.1538-7836.2003.00494.x","volume":"1","author":"Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilov S, Eskilson C, Andersson M, Freij A, Group ES","year":"2003","unstructured":"Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilov S, Eskilson C, Andersson M, Freij A, Group ES (2003) The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 1(12):2490\u20132496. https:\/\/doi.org\/10.1111\/j.1538-7836.2003.00494.x","journal-title":"J Thromb Haemost"},{"issue":"1","key":"742_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","volume":"4","author":"BI Eriksson","year":"2006","unstructured":"Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kalebo P, Investigators OD-HS (2006) Oral, direct factor Xa inhibition with BAY 59\u20137939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4(1):121\u2013128. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01657.x","journal-title":"J Thromb Haemost"},{"issue":"22","key":"742_CR40","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","volume":"114","author":"BI Eriksson","year":"2006","unstructured":"Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kalebo P, Investigators OD-HS (2006) A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59\u20137939), for thromboprophylaxis after total hip replacement. Circulation 114(22):2374\u20132381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.642074","journal-title":"Circulation"},{"issue":"5","key":"742_CR41","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.thromres.2006.12.025","volume":"120","author":"BI Eriksson","year":"2007","unstructured":"Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kalebo P (2007) Dose-escalation study of rivaroxaban (BAY 59\u20137939)\u2013an oral, direct factor Xa inhibitor\u2013for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res 120(5):685\u2013693. https:\/\/doi.org\/10.1016\/j.thromres.2006.12.025","journal-title":"Thromb Res"},{"issue":"26","key":"742_CR42","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","volume":"358","author":"Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, Group RS","year":"2008","unstructured":"Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, Group RS (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358(26):2765\u20132775. https:\/\/doi.org\/10.1056\/NEJMoa0800374","journal-title":"N Engl J Med"},{"key":"742_CR43","doi-asserted-by":"publisher","unstructured":"Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ, Group R-NIS (2011) Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost 105 (4):721\u2013729. doi: https:\/\/doi.org\/10.1160\/TH10-10-0679","DOI":"10.1160\/TH10-10-0679"},{"issue":"12","key":"742_CR44","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/j.arth.2014.05.029","volume":"29","author":"T Fuji","year":"2014","unstructured":"Fuji T, Wang CJ, Fujita S, Kawai Y, Kimura T, Tachibana S (2014) Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan. J Arthroplasty 29(12):2439\u20132446. https:\/\/doi.org\/10.1016\/j.arth.2014.05.029","journal-title":"J Arthroplasty"},{"key":"742_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12959-015-0057-x","volume":"13","author":"T Fuji","year":"2015","unstructured":"Fuji T, Fujita S, Kawai Y, Nakamura M, Kimura T, Fukuzawa M, Abe K, Tachibana S (2015) Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V. Thromb J 13:27. https:\/\/doi.org\/10.1186\/s12959-015-0057-x","journal-title":"Thromb J"},{"issue":"9632","key":"742_CR46","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, Investigators R (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(08)60880-6","journal-title":"Lancet"},{"issue":"26","key":"742_CR47","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","volume":"363","author":"MR Lassen","year":"2010","unstructured":"Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, Investigators A (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363(26):2487\u20132498. https:\/\/doi.org\/10.1056\/NEJMoa1006885","journal-title":"N Engl J Med"},{"issue":"9319","key":"742_CR48","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","volume":"359","author":"Lassen MR, Bauer KA, Eriksson BI, Turpie AG, European Pentasaccharide Elective Surgery Study Steering C","year":"2002","unstructured":"Lassen MR, Bauer KA, Eriksson BI, Turpie AG, European Pentasaccharide Elective Surgery Study Steering C (2002) Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359(9319):1715\u20131720. https:\/\/doi.org\/10.1016\/S0140-6736(02)08652-X","journal-title":"Lancet"},{"issue":"2","key":"742_CR49","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1302\/0301-620X.94B2.27850","volume":"94","author":"GE Raskob","year":"2012","unstructured":"Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR (2012) Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 94(2):257\u2013264. https:\/\/doi.org\/10.1302\/0301-620X.94B2.27850","journal-title":"J Bone Joint Surg Br"},{"issue":"6","key":"742_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250096","volume":"16","author":"T He","year":"2021","unstructured":"He T, Han F, Wang J, Hu Y, Zhu J (2021) Efficacy and safety of anticoagulants for postoperative thrombophylaxis in total hip and knee arthroplasty: a PRISMA-compliant Bayesian network meta-analysis. PLoS ONE 16(6):e0250096. https:\/\/doi.org\/10.1371\/journal.pone.0250096","journal-title":"PLoS ONE"},{"issue":"6","key":"742_CR51","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1177\/1076029612437579","volume":"18","author":"A Cohen","year":"2012","unstructured":"Cohen A, Drost P, Marchant N, Mitchell S, Orme M, Rublee D, Simon TA, Sutton A (2012) The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. Clin Appl Thromb Hemost 18(6):611\u2013627. https:\/\/doi.org\/10.1177\/1076029612437579","journal-title":"Clin Appl Thromb Hemost"},{"key":"742_CR52","unstructured":"Howick J CI, Glasziou P, Greenhalgh T, Carl Heneghan, Liberati A, Moschetti I, Phillips B, Thornton H, Goddard O, Hodgkinson M (2011) The 2011 Oxford CEBM Levels of Evidence. Oxford Centre for Evidence-Based Medicine https:\/\/www.cebmnet\/indexaspx?o=5653"},{"issue":"11","key":"742_CR53","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catala-Lopez F, Gotzsche PC, Dickersin K, Boutron I, Altman DG, Moher D (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"742_CR54","doi-asserted-by":"publisher","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 10:000142. doi: https:\/\/doi.org\/10.1002\/14651858.ED000142","DOI":"10.1002\/14651858.ED000142"},{"key":"742_CR55","unstructured":"Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA . Cochrane Handbook for Systematic Reviews of Interventions version 6.2. Cochrane 2021. Available from www.training.cochrane.org\/handbook. Accessed on February 2022."},{"issue":"9319","key":"742_CR56","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/s0140-6736(02)08652-x","volume":"359","author":"MR Lassen","year":"2002","unstructured":"Lassen MR, Bauer KA, Eriksson BI, Turpie AG (2002) Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359(9319):1715\u20131720. https:\/\/doi.org\/10.1016\/s0140-6736(02)08652-x","journal-title":"Lancet"},{"issue":"4","key":"742_CR57","doi-asserted-by":"publisher","first-page":"CD007557","DOI":"10.1002\/14651858.CD007557.pub3","volume":"4","author":"DR Junqueira","year":"2017","unstructured":"Junqueira DR, Zorzela LM, Perini E (2017) Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 4(4):CD007557. https:\/\/doi.org\/10.1002\/14651858.CD007557.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"2 Suppl","key":"742_CR58","doi-asserted-by":"publisher","first-page":"e278S","DOI":"10.1378\/chest.11-2404","volume":"141","author":"Y Falck-Ytter","year":"2012","unstructured":"Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr (2012) Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e278S-e325S. https:\/\/doi.org\/10.1378\/chest.11-2404","journal-title":"Chest"},{"issue":"3","key":"742_CR59","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11239-013-0889-9","volume":"35","author":"CW Francis","year":"2013","unstructured":"Francis CW (2013) Prevention of VTE in patients having major orthopedic surgery. J Thromb Thrombolysis 35(3):359\u2013367. https:\/\/doi.org\/10.1007\/s11239-013-0889-9","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"742_CR60","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/1076029614546328","volume":"21","author":"P Maniscalco","year":"2015","unstructured":"Maniscalco P, Caforio M, Imberti D, Porcellini G, Benedetti R (2015) Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review. Clin Appl Thromb Hemost 21(2):115\u2013119. https:\/\/doi.org\/10.1177\/1076029614546328","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"742_CR61","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1586\/17474086.2013.853430","volume":"6","author":"S Rachidi","year":"2013","unstructured":"Rachidi S, Aldin ES, Greenberg C, Sachs B, Streiff M, Zeidan AM (2013) The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Rev Hematol 6(6):677\u2013695. https:\/\/doi.org\/10.1586\/17474086.2013.853430","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"742_CR62","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/corr.0000000000000714","volume":"477","author":"P Kasina","year":"2019","unstructured":"Kasina P, Wall A, Lapidus LJ, Rolfson O, K\u00e4rrholm J, Nemes S, Eriksson BI, Mohaddes M (2019) Postoperative thromboprophylaxis with new oral anticoagulants is superior to LMWH in hip arthroplasty surgery: findings from the Swedish registry. Clin Orthop Relat Res 477(6):1335\u20131343. https:\/\/doi.org\/10.1097\/corr.0000000000000714","journal-title":"Clin Orthop Relat Res"},{"key":"742_CR63","unstructured":"Jupalli A, Iqbal AM (2022) Enoxaparin. In: StatPearls. StatPearls Publishing. Copyright \u00a9 2022, StatPearls Publishing LLC., Treasure Island (FL)."},{"issue":"12","key":"742_CR64","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2165\/00003088-200342120-00003","volume":"42","author":"J Fareed","year":"2003","unstructured":"Fareed J, Hoppensteadt D, Walenga J, Iqbal O, Ma Q, Jeske W, Sheikh T (2003) Pharmacodynamic and pharmacokinetic properties of enoxaparin\u202f: implications for clinical practice. Clin Pharmacokinet 42(12):1043\u20131057. https:\/\/doi.org\/10.2165\/00003088-200342120-00003","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"742_CR65","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1586\/erc.09.19","volume":"7","author":"SK Nadar","year":"2009","unstructured":"Nadar SK, Goyal D, Shantsila E, Banerjee P, Lip GY (2009) Fondaparinux: an overview. Expert Rev Cardiovasc Ther 7(6):577\u2013585. https:\/\/doi.org\/10.1586\/erc.09.19","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"10","key":"742_CR66","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","volume":"58","author":"W Byon","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE (2019) Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 58(10):1265\u20131279. https:\/\/doi.org\/10.1007\/s40262-019-00775-z","journal-title":"Clin Pharmacokinet"},{"key":"742_CR67","unstructured":"Singh R, Emmady PD (2022) Rivaroxaban. In: StatPearls. StatPearls Publishing"},{"issue":"6","key":"742_CR68","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","volume":"127","author":"MM Samama","year":"2011","unstructured":"Samama MM (2011) The mechanism of action of rivaroxaban\u2013an oral, direct factor Xa inhibitor\u2013compared with other anticoagulants. Thromb Res 127(6):497\u2013504. https:\/\/doi.org\/10.1016\/j.thromres.2010.09.008","journal-title":"Thromb Res"},{"key":"742_CR69","doi-asserted-by":"publisher","first-page":"7636104","DOI":"10.1155\/2020\/7636104","volume":"2020","author":"MTP Mujer","year":"2020","unstructured":"Mujer MTP, Rai MP, Atti V, Dimaandal IL, Chan AS, Shrotriya S, Gundabolu K, Dhakal P (2020) An update on the reversal of non-vitamin k antagonist oral anticoagulants. Adv Hematol 2020:7636104. https:\/\/doi.org\/10.1155\/2020\/7636104","journal-title":"Adv Hematol"},{"issue":"4","key":"742_CR70","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s11239-011-0551-3","volume":"31","author":"PC Wong","year":"2011","unstructured":"Wong PC, Pinto DJ, Zhang D (2011) Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 31(4):478\u2013492. https:\/\/doi.org\/10.1007\/s11239-011-0551-3","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"742_CR71","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3174\/ajnr.A3000","volume":"33","author":"J Comin","year":"2012","unstructured":"Comin J, Kallmes DF (2012) Dabigatran (Pradaxa). AJNR Am J Neuroradiol 33(3):426\u2013428. https:\/\/doi.org\/10.3174\/ajnr.A3000","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"742_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-9560-2-1","volume":"2","author":"R Altman","year":"2004","unstructured":"Altman R, Luciardi HL, Muntaner J, Herrera RN (2004) The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J 2(1):1. https:\/\/doi.org\/10.1186\/1477-9560-2-1","journal-title":"Thromb J"},{"issue":"3","key":"742_CR73","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2146\/ajhp150821","volume":"74","author":"M Poulakos","year":"2017","unstructured":"Poulakos M, Walker JN, Baig U, David T (2017) Edoxaban: a direct oral anticoagulant. Am J Health Syst Pharm 74(3):117\u2013129. https:\/\/doi.org\/10.2146\/ajhp150821","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"742_CR74","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/jth.12230","volume":"11","author":"G Raskob","year":"2013","unstructured":"Raskob G, B\u00fcller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, Mercuri M (2013) Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study\u2013methodological implications for clinical trials. J Thromb Haemost 11(7):1287\u20131294. https:\/\/doi.org\/10.1111\/jth.12230","journal-title":"J Thromb Haemost"},{"issue":"9632","key":"742_CR75","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(08)60880-6","volume":"372","author":"AK Kakkar","year":"2008","unstructured":"Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(08)60880-6","journal-title":"Lancet"},{"issue":"1","key":"742_CR76","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.rboe.2017.11.007","volume":"53","author":"JL Colleoni","year":"2018","unstructured":"Colleoni JL, Ribeiro FN, Mos PAC, Reis JP, Oliveira HR, Miura BK (2018) Venous thromboembolism prophylaxis after total knee arthroplasty (TKA): aspirin vs. rivaroxaban. Rev Bras Ortop 53(1):22\u201327. https:\/\/doi.org\/10.1016\/j.rboe.2017.11.007","journal-title":"Rev Bras Ortop"},{"issue":"12","key":"742_CR77","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3760\/cma.j.issn.0366-6999.20132175","volume":"127","author":"Y Jiang","year":"2014","unstructured":"Jiang Y, Du H, Liu J, Zhou Y (2014) Aspirin combined with mechanical measures to prevent venous thromboembolism after total knee arthroplasty: a randomized controlled trial. Chin Med J (Engl) 127(12):2201\u20132205","journal-title":"Chin Med J (Engl)"},{"issue":"7","key":"742_CR78","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/MBC.0000000000000121","volume":"25","author":"Y Zou","year":"2014","unstructured":"Zou Y, Tian S, Wang Y, Sun K (2014) Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coagul Fibrinolysis 25(7):660\u2013664. https:\/\/doi.org\/10.1097\/MBC.0000000000000121","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"742_CR79","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1046\/j.1365-2141.2002.03233.x","volume":"116","author":"MA Crowther","year":"2002","unstructured":"Crowther MA, Berry LR, Monagle PT, Chan AK (2002) Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116(1):178\u2013186. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03233.x","journal-title":"Br J Haematol"}],"container-title":["Journal of Orthopaedics and Traumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10195-023-00742-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10195-023-00742-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10195-023-00742-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T19:34:26Z","timestamp":1731008066000},"score":1,"resource":{"primary":{"URL":"https:\/\/jorthoptraumatol.springeropen.com\/articles\/10.1186\/s10195-023-00742-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,9]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["742"],"URL":"https:\/\/doi.org\/10.1186\/s10195-023-00742-2","relation":{},"ISSN":["1590-9999"],"issn-type":[{"value":"1590-9999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,9]]},"assertion":[{"value":"6 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}},{"value":"The authors declare that they have any competing interests in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}